Several recent survey results, including from the Pew Research Center, show an increase in support and interest in cannabis in the US.
Legalization of cannabis in the United States | Image Credit: © VladimirKoval stock.adobe.com
On March 26, 2024, Pew Research Center released a report on survey results regarding opinions on cannabis in the US (1). The study was conducted from January 16–21, 2024 and collected data from 5,140 adults representative of the US population in several categories (1). One of the major findings was that only 11% of respondents stated that cannabis should not be legal at all (1). The majority (57% of respondents) stated that cannabis should be legal for both recreational and medical uses, and 32% stated that it should be legal for medical uses only (1). “Opinions about marijuana legalization have changed little over the past five years,” the report noted (1).
The study also reported data on the perceived impacts of cannabis legalization, with 52% of respondents stating that legalizing cannabis is good for local economies, 29% stating that it produces no effect, and 17% stating that it is bad for local economies (1). “More adults also say legalizing marijuana for recreational use makes the criminal justice system more fair (42%) than less fair (18%); 38% say it has no impact,” the study added (1).
The study also broke down the data based on partisan differences, ages, and race and ethnicity, observing several conclusions including (1):
In a separate study, Pew Research Center also recently collected data on the number of Americans living in states with legal cannabis and on the number of dispensaries in each state (2). In February 2024, it reported that 79% of all Americans live in a state with at least one cannabis dispensary, with California having the most dispensaries by far—over 3600 out of the 15,000 total in the US (2). “These changes in state law come as a broad majority of Americans say marijuana should be legal in some way,” the study noted, citing its 2022 survey (2). Additionally, most Americans (54%) live in a state with legal recreational cannabis, and 74% live in a state with either medical or recreational cannabis (2).
According to a report earlier this year from BioWellnessX, a producer of hemp-derived tetrahydrocannabinol (THC) products, search trends indicated that Mississippi residents have shown the most interest in medical cannabis in 2024 (3). After analyzing state populations and monthly search data from Google on keywords related to medical cannabis, Mississippi showed 294.59 searches per 100,000 residents, followed by Arkansas and Alaska with 233 and 222 searches per 100,000 residents, respectively (3). There were nearly 500,000 monthly searches nationwide (3). “A total of 488,230 monthly searches nationwide signifies that medical marijuana has become a mainstream topic across the US,” the study stated (3).
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.